Skip to content
Menu

Zeev Bovan

688 posts

Posts (688)

Zeev Bovan AMD 6 months ago #421

It’s probably going to where all fomo pump end up. It’s abnormal the AMD is that expensive.

Zeev Bovan TARA 6 months ago #422

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
Protara TherapeuticsApril 27, 2026 16:05 ET
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated, interim data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial evaluating TARA-002 in patients with BCG-Naïve non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming American Urological Association (AUA) 2026 Annual Meeting taking place from May 15, 2026 to May 18, 2026 in Washington, DC.

The presentation will include data from the abstract published on the AUA website, as well as updated safety and efficacy data as of an April 5, 2026 data cutoff from 31 enrolled BCG-Naïve patients. A second poster presentation will feature previously reported data from the ADVANCED-2 trial cohort of BCG-Unresponsive patients that was originally presented at the ASCO Genitourinary Cancers Symposium in February 2026.

ADVANCED-2 (NCT05951179) is a Phase 2 open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive or BCG-Naïve. Trial subjects received an induction course, with or without a reinduction, of six weekly intravesical instillations of TARA-002, followed by a maintenance course of three weekly instillations every three months.

BCG-Naïve Poster Presentation Details:

Title: ADVANCED-2 (Cohort A): Preliminary Efficacy and Safety Data In BCG-Naïve Participants with High-Grade Non-Muscle Invasive Bladder Cancer
Session: Bladder Cancer: Non-invasive I
Presenter: Mark Tyson, M.D., MPH, Vice Chair for Research and a Professor in the Department of Urology with the Mayo Clinic in Phoenix, Arizona
Session Date and Time: Friday, May 15, 2026, at 7:00 a.m. – 9:00 a.m.
BCG-Unresponsive Encore Poster Presentation Details:

Title: ADVANCED-2 (Cohort B): Interim Efficacy and Safety Data in BCG-Unresponsive Participants with High-Grade Non-Muscle Invasive Bladder Cancer
Session: Bladder Cancer: Non-invasive II
Presenter: Timothy Clinton, M.D., Associate Surgeon with the Brigham and Women’s Hospital in Boston, Massachusetts
Session Date and Time: Friday, May 15, 2026, at 3:30 p.m. – 5:30 p.m.

Zeev Bovan NOK 6 months ago #423

Do be surprised if in 5-10 years this stock will be traded hundreds of percent from the price it is traded right now $NOK.

Zeev Bovan AMD 6 months ago #425

Sell American money destroyer before it destroy your portfolio

Zeev Bovan B 6 months ago #428

When silver and gold skyrocket $B will follow.

Zeev Bovan AMD 6 months ago #430

$TARA
As of April 2026, Protara Therapeutics (TARA) is a clinical-stage biotech stock with a "Strong Buy" consensus, trading around $5.13 with a 12-month average price target of $23.75. The company focuses on TARA-002 for cancer and rare diseases, recently reporting positive interim phase 2 data and a 68% complete response rate in NMIBC patients.
MSN
MSN
+2
Key Recent Developments & Stock News:
Analyst Outlook: Analysts have a "Strong Buy" consensus, with targets ranging from $21 to $27, indicating a high potential upside from current levels.
Clinical Progress: TARA-002, the company's lead program, showed 68% complete response rates at six months in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).